SCHEMBL5653528

SCHEMBL5653528

CCOC(=O)[C@@H](Cc1ccccc1)[C@@](N)(O)C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 2/20 0.52
CTRB1 P17538 1/20 0.46
ALDH1A1 P00352 3/20 0.45
RECQL P46063 1/20 0.45
PKM P14618 1/20 0.44
EPHX2 P34913 1/20 0.44
PPARG P37231 1/20 0.44
TP53 P04637 1/20 0.44
NPY1R P25929 1/20 0.43
NPY2R P49146 1/20 0.43
HPRT1 P00492 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PPID Q08752 1/20 0.43
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650006 1.00 MMP8 (0.52) MMP8CTRB1ALDH1A1RECQLPKM
SCHEMBL5651363 0.88 MMP8 (0.51) MMP8ALDH1A1PKMEPHX2PPARG
SCHEMBL5651688 0.88 MMP8 (0.51) MMP8ALDH1A1PKMEPHX2PPARG
SCHEMBL6075140 0.82 MMP8 (0.44) MMP8CTRB1ALDH1A1RECQLPKM
SCHEMBL6074673 0.82 MMP8 (0.44) MMP8CTRB1ALDH1A1RECQLPKM
SCHEMBL15930101 0.80 MMP8 (0.55) MMP8ALDH1A1RECQLPKMEPHX2
SCHEMBL14770008 0.80 MMP8 (0.55) MMP8ALDH1A1RECQLPKMEPHX2
SCHEMBL6708542 0.80 MMP8 (0.49) MMP8ALDH1A1PKMEPHX2PPARG
SCHEMBL304717 0.80 MMP8 (0.49) MMP8ALDH1A1RECQLPKMEPHX2
SCHEMBL5728110 0.77 MMP8 (0.49) MMP8ALDH1A1RECQLPKMEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307184-B2 Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds KANEKA CORPORATION (JP) 2007-12-11 US disclosed
US-20040181074-A1 Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound KANEKA CORPORATION (JP) 2004-09-16 US disclosed
EP-1300391-A1 PROCESS FOR PRODUCING 3-AMINO-2-HYDROXYPROPIONIC ACID DERIVATIVES KANEKA CORPORATION (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181074-A1 Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound HNMT, PNMT, HRH4 MMP8 4042/4885CTRB1 4138/4885ALDH1A1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.